Novel oral plasminogen activator inhibitor‑1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats

Noguchi,Ryuichi; Kaji,Kosuke; Namisaki,Tadashi; Moriya,Kei; Kawaratani,Hideto; Kitade,Mitsuteru; Takaya,Hiroaki; Aihara,Yosuke; Douhara,Akitoshi; Asada,Kiyoshi; Nishimura,Norihisa; Miyata,Toshio; Yoshiji,Hitoshi

doi:10.3892/mmr.2020.11360

Novel oral plasminogen activator inhibitor‑1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats

Authors:
- Ryuichi Noguchi
- Kosuke Kaji
- Tadashi Namisaki
- Kei Moriya
- Hideto Kawaratani
- Mitsuteru Kitade
- Hiroaki Takaya
- Yosuke Aihara
- Akitoshi Douhara
- Kiyoshi Asada
- Norihisa Nishimura
- Toshio Miyata
- Hitoshi Yoshiji
View Affiliations

Affiliations: Department of Gastroenterology, Nara Medical University, Kashihara, Nara 634‑8522, Japan, United Centers for Advanced Research and Translational Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980‑8575, Japan
Published online on: July 28, 2020 https://doi.org/10.3892/mmr.2020.11360
Pages: 2948-2956
Copyright: © Noguchi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

An orally bioavailable small molecule inhibitor of plasminogen activator inhibitor‑1 (PAI‑1) is currently being clinically assessed as a novel antithrombotic agent. Although PAI‑1 is known to serve a key role in the pathogenesis of metabolic syndrome (MetS) including nonalcoholic steatohepatitis (NASH), the pharmacological action of an oral PAI‑1 inhibitor against the development of MetS‑related liver fibrosis remains unclear. The current study was designed to explicate the effect of TM5275, an oral PAI‑1 inhibitor, on MetS‑related hepatic fibrogenesis. The in vivo antifibrotic effect of orally administered TM5275 was investigated in two different rat MetS models. Fischer 344 rats received a choline‑deficient L‑amino‑acid‑defined diet for 12 weeks to induce steatohepatitis with development of severe hepatic fibrosis. Otsuka Long‑Evans Tokushima Fatty rats, used to model congenital diabetes, underwent intraperitoneal injection of porcine serum for 6 weeks to induce hepatic fibrosis under diabetic conditions. In each experimental model, TM5275 markedly ameliorated the development of hepatic fibrosis and suppressed the proliferation of activated hepatic stellate cells (HSCs). Additionally, the hepatic production of tumor growth factor (TGF)‑β1 and total collagen was suppressed. In vitro assays revealed that TGF‑β1 stimulated the upregulation of Serpine1 mRNA expression, which was inhibited by TM5275 treatment in cultured HSC‑T6 cells, a rat HSC cell line. Furthermore, TM5275 substantially attenuated the TGF‑β1‑stimulated proliferative and fibrogenic activity of HSCs by inhibiting AKT phosphorylation. Collectively, TM5275 demonstrated an antifibrotic effect on liver fibrosis in different rat MetS models, suppressing TGF‑β1‑induced HSC proliferation and collagen synthesis. Thus, PAI‑1 inhibitors may serve as effective future therapeutic agents against NASH‑based hepatic fibrosis.

View Figures

View References

1	Farrell GC and Larter CZ: Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology. 43:2948–S112. 2006. View Article : Google Scholar
2	Angulo P: Nonalcoholic fatty liver disease. N Engl J Med. 346:1221–1231. 2002. View Article : Google Scholar : PubMed/NCBI
3	Sanyal AJ, Neuschwander-Tetri BA and Tonascia L: End points must be clinically meaningful for drug development in nonalcoholic fatty liver disease. Gastroenterology. 150:11–13. 2016. View Article : Google Scholar : PubMed/NCBI
4	Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L and Wymer M: Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 64:73–84. 2016. View Article : Google Scholar : PubMed/NCBI
5	Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, Sebastiani G, Ekstedt M, Hagstrom H, Nasr P, et al: Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 65:1557–1565. 2017. View Article : Google Scholar : PubMed/NCBI
6	Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, et al: Liver fibrosis, but No other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 149:389–397 e10. 2015. View Article : Google Scholar : PubMed/NCBI
7	Erickson LA, Ginsberg MH and Loskutoff DJ: Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest. 74:1465–1472. 1984. View Article : Google Scholar : PubMed/NCBI
8	Providence KM and Higgins PJ: PAI-1 expression is required for epithelial cell migration in two distinct phases of in vitro wound repair. J Cell Physiol. 200:297–308. 2004. View Article : Google Scholar : PubMed/NCBI
9	Toriseva M and Kähäri VM: Proteinases in cutaneous wound healing. Cell Mol Life Sci. 66:203–224. 2009. View Article : Google Scholar : PubMed/NCBI
10	Lazar MH, Christensen PJ, Du M, Yu B, Subbotina NM, Hanson KE, Hansen JM, White ES, Simon RH and Sisson TH: Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin. Am J Respir Cell Mol Biol. 31:672–678. 2004. View Article : Google Scholar : PubMed/NCBI
11	Takeshita K, Hayashi M, Iino S, Kondo T, Inden Y, Iwase M, Kojima T, Hirai M, Ito M, Loskutoff DJ, et al: Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction. Am J Pathol. 164:449–456. 2004. View Article : Google Scholar : PubMed/NCBI
12	Ma LJ and Fogo AB: PAI-1 and kidney fibrosis. Front Biosci (Landmark Ed). 14:2028–2041. 2009. View Article : Google Scholar : PubMed/NCBI
13	Clouthier DE, Comerford SA and Hammer RE: Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice. J Clin Invest. 100:2697–2713. 1997. View Article : Google Scholar : PubMed/NCBI
14	Wang H, Zhang Y and Heuckeroth RO: PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA. FEBS Lett. 581:3098–3104. 2007. View Article : Google Scholar : PubMed/NCBI
15	Ajmera V, Perito ER, Bass NM, Terrault NA, Yates KP, Gill R, Loomba R, Diehl AM and Aouizerat BE; NASH Clinical Research Network, : Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology. 65:65–77. 2017. View Article : Google Scholar : PubMed/NCBI
16	Hu PF, Chen H, Zhong W, Lin Y, Zhang X, Chen YX and Xie WF: Adenovirus-mediated transfer of siRNA against PAI-1 mRNA ameliorates hepatic fibrosis in rats. J Hepatol. 51:102–113. 2009. View Article : Google Scholar : PubMed/NCBI
17	Izuhara Y, Yamaoka N, Kodama H, Dan T, Takizawa S, Hirayama N, Meguro K, van Ypersele de Strihou C and Miyata T: A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J Cereb Blood Flow Metab. 30:904–912. 2010. View Article : Google Scholar : PubMed/NCBI
18	Tashiro Y, Nishida C, Sato-Kusubata K, Ohki-Koizumi M, Ishihara M, Sato A, Gritli I, Komiyama H, Sato Y, Dan T, et al: Inhibition of PAI-1 induces neutrophil-driven neoangiogenesis and promotes tissue regeneration via production of angiocrine factors in mice. Blood. 119:6382–6393. 2012. View Article : Google Scholar : PubMed/NCBI
19	Imai J, Yahata T, Ichikawa H, Ibrahim AA, Yazawa M, Sumiyoshi H, Inagaki Y, Matsushima M, Suzuki T, Mine T, Ando K, et al: Inhibition of plasminogen activator inhibitor-1 attenuates against intestinal fibrosis in mice. Intest Res. 18:219–228. 2020. View Article : Google Scholar : PubMed/NCBI
20	Lee SM, Dorotea D, Jung I, Nakabayashi T, Miyata T and Ha H: TM5441, a plasminogen activator inhibitor-1 inhibitor, protects against high fat diet-induced non-alcoholic fatty liver disease. Oncotarget. 8:89746–89760. 2017. View Article : Google Scholar : PubMed/NCBI
21	Henkel AS, Khan SS, Olivares S, Miyata T and Vaughan DE: Inhibition of plasminogen activator inhibitor 1 attenuates hepatic steatosis but does not prevent progressive nonalcoholic steatohepatitis in mice. Hepatol Commun. 2:1479–1492. 2018. View Article : Google Scholar : PubMed/NCBI
22	Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G and Quon MJ: Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 85:2402–2410. 2000. View Article : Google Scholar : PubMed/NCBI
23	Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41:1313–1321. 2005. View Article : Google Scholar : PubMed/NCBI
24	Kaji K, Yoshiji H, Kitade M, Ikenaka Y, Noguchi R, Yoshii J, Yanase K, Namisaki T, Yamazaki M, Moriya K, et al: Impact of insulin resistance on the progression of chronic liver diseases. Int J Mol Med. 22:801–808. 2008.PubMed/NCBI
25	Tsuchida T and Friedman SL: Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 14:397–411. 2017. View Article : Google Scholar : PubMed/NCBI
26	Ozutsumi T, Namisaki T, Shimozato N, Kaji K, Tsuji Y, Kaya D, Fujinaga Y, Furukawa M, Nakanishi K, Sato S, et al: Combined treatment with sodium-glucose cotransporter-2 inhibitor (Canagliflozin) and dipeptidyl peptidase-4 inhibitor (teneligliptin) alleviates NASH progression in A non-diabetic rat model of steatohepatitis. Int J Mol Sci. 21:21642020. View Article : Google Scholar
27	Gleizes PE, Munger JS, Nunes I, Harpel JG, Mazzieri R, Noguera I and Rifkin DB: TGF-beta latency: Biological significance and mechanisms of activation. Stem Cells. 15:190–197. 1997. View Article : Google Scholar : PubMed/NCBI
28	Mulligan-Kehoe MJ, Schwartz GN and Zacharski LR: The functions of plasminogen activator inhibitor-1: Do we have all the pieces of PAI? Thromb Res. 117:483–486. 2006. View Article : Google Scholar : PubMed/NCBI
29	Bajou K, Noël A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D and Foidart JM: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med. 4:923–928. 1998. View Article : Google Scholar : PubMed/NCBI
30	Zhang LP, Takahara T, Yata Y, Furui K, Jin B, Kawada N and Watanabe A: Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: Role of stellate cells. J Hepatol. 31:703–711. 1999. View Article : Google Scholar : PubMed/NCBI
31	Seki T, Imai H, Uno S, Ariga T and Gelehrter TD: Production of tissue-type plasminogen activator (t-PA) and type-1 plasminogen activator inhibitor (PAI-1) in mildly cirrhotic rat liver. Thromb Haemost. 75:801–807. 1996. View Article : Google Scholar : PubMed/NCBI
32	Leyland H, Gentry J, Arthur MJ and Benyon RC: The plasminogen-activating system in hepatic stellate cells. Hepatology. 24:1172–1178. 1996. View Article : Google Scholar : PubMed/NCBI
33	Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S and Gauthier JM: Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 17:3091–3100. 1998. View Article : Google Scholar : PubMed/NCBI
34	Okada H, Woodcock-Mitchell J, Mitchell J, Sakamoto T, Marutsuka K, Sobel BE and Fujii S: Induction of plasminogen activator inhibitor type 1 and type 1 collagen expression in rat cardiac microvascular endothelial cells by interleukin-1 and its dependence on oxygen-centered free radicals. Circulation. 97:2175–2182. 1998. View Article : Google Scholar : PubMed/NCBI
35	Crandall DL, Groeling TM, Busler DE and Antrilli TM: Release of PAI-1 by human preadipocytes and adipocytes independent of insulin and IGF-1. Biochem Biophys Res Commun. 279:984–988. 2000. View Article : Google Scholar : PubMed/NCBI
36	Wilkins-Port CE, Ye Q, Mazurkiewicz JE and Higgins PJ: TGF-beta1 + EGF-initiated invasive potential in transformed human keratinocytes is coupled to a plasmin/MMP-10/MMP-1-dependent collagen remodeling axis: Role for PAI-1. Cancer Res. 69:4081–4091. 2009. View Article : Google Scholar : PubMed/NCBI
37	Su EJ, Fredriksson L, Schielke GP, Eriksson U and Lawrence DA: Tissue plasminogen activator-mediated PDGF signaling and neurovascular coupling in stroke. J Thromb Haemost. 7 (Suppl 1):S155–S158. 2009. View Article : Google Scholar
38	Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER and Brenner DA: The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo. J Hepatol. 30:77–87. 1999. View Article : Google Scholar : PubMed/NCBI
39	Kanzler S, Lohse AW, Keil A, Henninger J, Dienes HP, Schirmacher P, Rose-John S, zum Büschenfelde KH and Blessing M: TGF-beta1 in liver fibrosis: An inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol. 276:G1059–G1068. 1999.PubMed/NCBI
40	Derynck R and Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
41	Motojima M, Kakuchi J and Yoshioka T: Association of TGF-beta signaling in angiotensin II-induced PAI-1 mRNA upregulation in mesangial cells: Role of PKC. Biochim Biophys Acta. 1449:217–226. 1999. View Article : Google Scholar : PubMed/NCBI
42	Dong C, Zhu S, Alvarez RJ and Goldschmidt-Clermont PJ: Angiotensin II induces PAI-1 expression through MAP kinase-dependent, but TGF beta and PI3 kinase-independent pathway. J Heart Lung Transplant. 20:226–227. 2001. View Article : Google Scholar : PubMed/NCBI
43	Samarakoon R, Higgins SP, Higgins CE and Higgins PJ: TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/ EGFR(Y845) and Rho/ROCK signaling. J Mol Cell Cardiol. 44:527–538. 2008. View Article : Google Scholar : PubMed/NCBI
44	Chanda D, Lee CH, Kim YH, Noh JR, Kim DK, Park JH, Hwang JH, Lee MR, Jeong KH, Lee IK, et al: Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner. Hepatology. 50:880–892. 2009. View Article : Google Scholar : PubMed/NCBI